Calando Publishes new Results of siRNA Delivery Using its RONDEL™ Technology in Sepsis
Complete the form below to unlock access to ALL audio articles.
Calando Pharmaceuticals has announced the online publication in the journal Shock of the first investigation of siRNA formulated with Calando’s RONDEL™ nucleic acid delivery technology for the treatment of sepsis in mice.
This work was done in collaboration with Dr. Richard Hotchkiss and colleagues in the School of Medicine at Washington University in St. Louis. RONDEL™-mediated delivery of anti-apoptotic siRNA to lymphocytes of septic mice is shown to reverse the depletion of immune cells that is a hallmark of this disease.
“The publication demonstrates that the utility of Calando’s RONDEL™ nucleic acid delivery technology can extend beyond oncology to other therapeutics areas, such as sepsis,” said Dr. Heidel, Calando’s Chief Scientific Officer for Nucleic Acid Delivery. “We will continue to evaluate RONDEL™-formulated nucleic acids in a variety of therapeutic applications to complement our ongoing clinical and pre-clinical programs in oncology.”
Calando currently has two RNAi therapeutic candidates, CALAA-01 and CALAA-02, both in oncology. CALAA-01 is being investigated in an ongoing Phase I clinical trial, and CALAA-02 is currently in pre-clinical development with intended advancement into the clinic in 2009.
